Recursion Pharmaceuticals, Inc.
RXRX
$4.94
$0.163.35%
NASDAQ
Recommendation
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
--
P/E (TTM)
--
EPS (TTM)
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 15.11% | -13.18% | -86.67% | 1.74% | -6.75% |
| Total Depreciation and Amortization | 23.37% | 49.26% | 79.92% | -19.74% | 21.57% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -36.06% | 28.27% | 66.25% | 95.46% | -24.58% |
| Change in Net Operating Assets | 700.70% | -196.76% | 126.86% | 136.35% | 79.88% |
| Cash from Operations | 42.09% | -14.32% | -94.90% | 27.97% | 19.63% |
| Capital Expenditure | -71.94% | -41.14% | 71.55% | -285.96% | 82.23% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | 100.00% | -- | -- | -- | -- |
| Other Investing Activities | -165.80% | -185.71% | -- | 100.00% | -- |
| Cash from Investing | 20.11% | -102.64% | 6,138.05% | -9.09% | 37.14% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -1.81% | 2.57% | 8.13% | -8,696.15% | 0.00% |
| Issuance of Common Stock | 141.33% | 234.18% | -32.05% | -92.88% | 1,790.02% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 140.97% | 280.93% | -35.37% | -93.74% | 1,793.37% |
| Foreign Exchange rate Adjustments | 91.50% | 239.20% | -961.54% | 441.53% | 46.12% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 126.30% | -156.14% | 456.32% | -126.57% | 285.36% |